CeriBell, Inc.
NASDAQ:CBLLMedical - Devices
+$0.25 today
- Market cap
- $995.34M
- Beta
- 0.84
- P/E (TTM)
- -10.9
- EPS (TTM)
- -$1.60
Volume 0.41M
Average 0.29M
CBLL EBITDA Margin
EBITDA as a percentage of revenue.
CeriBell, Inc.NASDAQ: CBLL
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin narrows to -72.0%
EBITDA Margin was -72.0% in Q1 FY2026, down 13.5 pp from a year earlier. On a trailing-twelve-month basis it was -60.2%, down 2.1 pp year over year. Over 3 fiscal years it widened by 78.9 pp.
Context
- EBITDA Margin widened in 3 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 6 analysts of -60.4% for the fiscal year ending Dec 2026, down from -56.3% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -72.0%-20.4 pp QoQ
- Last fiscal yearDec 2025
- -56.3%+0.7 pp YoY
- LTMMar 2026
- -60.2%-2.1 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -13.5 pp | -3.4 pp | +10.1 pp |
| 1 year | +0.7 pp | -4.1 pp | -4.7 pp |
| 3 years | +78.9 pp | +27.4 pp | -51.5 pp |
| 5 years | +43.7 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -56.3%
- Year-over-year change
- +0.7pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -56.3% | +0.7pp |
| FY2024 | 2024-12-31 | -57.0% | +1.6pp |
| FY2023 | 2023-12-31 | -58.6% | +76.6pp |
| FY2022 | 2022-12-31 | -135.3% | — |
EBITDA Margin vs competitors
How CBLL compares with its peers on the latest reported figures
- CBLL's LTM Mar 2026 EBITDA Margin of -60.2% is the 6th highest of the 7 companies compared; the peer median is -15.4%.
- Its year-over-year change of -2.1 pp is the lowest of 7, against a peer median of +8.2 pp.
- Over three fiscal years its change of +78.9 pp compares with a peer median of +66.2 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 22.4% | +7.2 pp | +64.1 pp | |
| LTM Sep 2026 | 14.0% | +20.0 pp | -12.4 pp | |
| LTM Mar 2026 | -13.9% | +3.1 pp | +68.3 pp | |
| LTM Mar 2026 | -17.0% | +26.6 pp | +30.8 pp | |
| LTM Mar 2026 | -38.0% | +3.6 pp | +219.5 pp | |
CBLLCeriBell, Inc. | LTM Mar 2026 | -60.2% | -2.1 pp | +78.9 pp |
| LTM Mar 2026 | -77.8% | +9.1 pp | +98.8 pp | |
| Peer median (excluding CBLL) | -15.4% | +8.2 pp | +66.2 pp | |
Competitors are the stored peer set for CBLL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 25.92M | 45.23M | 65.44M | 89.06M |
| Cost of Revenue | 4.43M | 7.06M | 8.69M | 10.79M |
| Gross Profit | 21.49M | 38.16M | 56.75M | 78.27M |
| Gross Margin | 82.9% | 84.4% | 86.7% | 87.9% |
| Research & Development | 7.24M | 9M | 13.56M | 19.14M |
| Selling, General & Admin | 50.27M | 59.21M | 82.9M | 117.53M |
| Operating Expenses | 57.51M | 68.2M | 96.46M | 136.68M |
| Depreciation & Amortization | 497K | 847K | 1.14M | 1.34M |
| EBITDA | (35.06M) | (26.51M) | (37.32M) | (50.18M) |
| EBITDA Margin | -135.3% | -58.6% | -57.0% | -56.3% |
| Operating Income | (36.02M) | (30.04M) | (39.71M) | (58.4M) |
| Operating Margin | -139.0% | -66.4% | -60.7% | -65.6% |
| Interest Income | 0 | 0 | 0 | 0 |
| Interest Expense | 1.6M | 2.1M | 1.99M | 1.89M |
| Other Income / Expenses | (1.14M) | 588K | (746K) | 4.99M |
| Income Before Tax | (37.16M) | (29.45M) | (40.46M) | (53.41M) |
| Pre-Tax Margin | -143.4% | -65.1% | -61.8% | -60.0% |
| Income Tax Expense | 2K | 11K | 0 | 0 |
| Net Income | (37.16M) | (29.46M) | (40.46M) | (53.41M) |
| Net Margin | -143.4% | -65.1% | -61.8% | -60.0% |
| EPS (Basic) | (1.59) | (1.26) | (3.39) | (1.46) |
| EPS (Diluted) | (1.59) | (1.26) | (3.39) | (1.46) |
| Weighted Avg Shares | 23.32M | 23.32M | 11.95M | 36.54M |
| Weighted Avg Shares (Diluted) | 23.32M | 23.32M | 11.95M | 36.54M |
CeriBell, Inc.
NASDAQ:CBLL
Intrinsic Alpha fair value
Locked
Current Price
$25.63
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.